• Home
  • MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.

Author List
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A
Publication
The Journal of experimental medicine
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1161566
Publication Year
2012
PubMed ID
22430491
Publication Title
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012 Apr 09; 209(4):679-96.